Is Kalaris Therapeutics Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Kalaris Therapeutics Inc (KLRS) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Kalaris Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Kalaris Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Kalaris Therapeutics Inc?

Muslim investors may consider investing in Kalaris Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Kalaris Therapeutics Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Kalaris Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Kalaris Therapeutics Inc updated?

The Shariah compliance status of Kalaris Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Kalaris Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Kalaris Therapeutics Inc?

You can check the latest Shariah compliance status of Kalaris Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

KLRS Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 18, 2026

Report Source: 2025 Annual Report

Kalaris Therapeutics Inc. Stock Analysis KLRS

United States Health Care Micro Cap Report: 2025 Annual

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. The company is headquartered in Berkeley Heights, New Jersey and currently employs 20 full-time employees. The company went IPO on 2020-07-30. The firm is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).

Key Statistics of Kalaris Therapeutics Inc (KLRS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$4.90$5.29

Today's Open

$5.29

Volume

33.84K

P/E Ratio (TTM)

52 Week Range

$2.14$11.88

Market Cap

111.11M

Avg. Volume

101.43K

Dividend Yield

Financial Metrics & Statements of Kalaris Therapeutics Inc (KLRS)

FAQ's for Kalaris Therapeutics Inc (KLRS)

According to Musaffa’s Shariah screening methodology, Kalaris Therapeutics Inc (KLRS) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.